JAK1 and rheumatoid arthritis: Although fewer studies have evaluated baricitinib and upadacitinib for an increased risk for these conditions, the FDA ruled that because they share a mechanism (JAK1 inhibition) and are indicated for the treatment of RA and inflammatory conditions, such as AD, they may carry the same risks to these patient populations.